/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Howard A. Burris

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

1.1K

Papers

71.6K

Citations

117

h-index

543

i10-index

Howard A. Burris is an academic researcher. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Lung Cancer Treatments and Mutations & HER2/EGFR in Cancer Research. The author has an h-index of 117, co-authored 969 publications.

ORCID: 0000-0002-1501-2931

Research Topics

Cancer Treatment and Pharmacology Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies Advanced Breast Cancer Therapies

Papers by this author

works

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

2016 · New England Journal of Medicine · 1,957 citations

https://doi.org/10.1056/nejmoa1609709

Gabriel N. Hortobágyi Salomon M. Stemmer Howard A. Burris Yoon Sim Yap

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

2022 · NEJM Evidence · 986 citations

https://doi.org/10.1056/evidoa2200015

Do‐Youn Oh Aiwu Ruth He Shukui Qin Li‐Tzong Chen

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

2010 · Journal of Clinical Oncology · 758 citations

https://doi.org/10.1200/jco.2010.29.5865

Howard A. Burris Hope S. Rugo Svetislava J. Vukelja Charles L. Vogel

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 · Journal of Clinical Oncology · 622 citations

https://doi.org/10.1200/jco.2005.16.584

Howard A. Burris Herbert I. Hurwitz Elizabeth Claire Dees Afshin Dowlati

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

2010 · Journal of Clinical Oncology · 591 citations

https://doi.org/10.1200/jco.2009.26.2071

Ian E. Krop Muralidhar Beeram Shanu Modi Suzanne F. Jones

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 · The Lancet Oncology · 548 citations

https://doi.org/10.1016/s1470-2045(18)30904-5

Funda Meric‐Bernstam Herbert I. Hurwitz Kanwal Raghav Robert R. McWilliams

Research topics

topics

Cancer Treatment and Pharmacology

Lung Cancer Treatments and Mutations

HER2/EGFR in Cancer Research

Colorectal Cancer Treatments and Studies

Advanced Breast Cancer Therapies

Chat about Author

Papers

Chat

Click to start Chat